{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:08:08Z","timestamp":1765807688056,"version":"3.40.5"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s203753","type":"journal-article","created":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T23:36:21Z","timestamp":1558913781000},"page":"97-99","source":"Crossref","is-referenced-by-count":2,"title":["<p>Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)<\/p>"],"prefix":"10.2147","volume":"Volume 13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5539-4404","authenticated-orcid":true,"given":"Farhad","family":"Salehzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0037-7823","authenticated-orcid":true,"given":"Yousef","family":"Mohammadikebar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6967-6429","authenticated-orcid":true,"given":"Afsaneh","family":"Enteshary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Ghanbarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Mirzarahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,5]]},"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=50143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=50143","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,26]],"date-time":"2019-05-26T23:36:22Z","timestamp":1558913782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/infliximab-in-treatment-of-idiopathic-refractory-childhood-pyoderma-ga-peer-reviewed-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/btt.s203753","relation":{},"ISSN":["1177-5491"],"issn-type":[{"type":"electronic","value":"1177-5491"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}